FORMULATION AND CHARACTERIZATION OF LIQUISOLID TABLETS FOR IMPROVING DISSOLUTION OF TELMISARTAN

Yıl 2025, Cilt: 50 Sayı: 1, 51 - 64, 25.03.2025

Dr Chinmaya Keshari Sahoo , Nidhi Shree Amiyakanta Mishra

https://doi.org/10.55262/fabadeczacilik.1518230

Öz

The current study's objective was to create liquisolid tablets (LST) in order to improve the dissolution profile of telmisartan, a poorly soluble medication (BCS class II). To prepare LST, the following ingredients were used: microcrystalline cellulose (MCC) as the carrier, PEG as the vehicle, croscarmelose sodium (CCS) as the superdisintegrant, and Aerosil 200 as the coating material. The tablet quality control tests, flow characteristics, and interactions between the medication and excipient were assessed for each formulation. Higuchi, Korsmeyer-Peppas, zero order, and first order pharmacokinetic models were used to examine the in vitro drug release (IVDR) kinetics for various batches. When the optimized formulation was evaluated for stability at 75±5% RH and 40±2ºC, it was shown to be stable for up to three months. No interaction between the medication and excipients was confirmed by Fourier Transform Infrared Spectroscopy (FTIR) investigations. The solubility studies were used to guide the selection of dissolution medium. Comparing the optimized formulation (TC3) to the traditional marketed formulation (TELVAS 20), a notable improvement in dissolution was observed. After three months of storage, there was no discernible change in the tablet's characteristics or the drug release profile.

Anahtar Kelimeler

BCS, LST, Dissolution, IVDR, Stability study.

Etik Beyan

Not applicable

Destekleyen Kurum

College of Pharmaceutical Sciences, Puri

Proje Numarası

PG Project

Teşekkür

The authors would like to thank the College of Pharmaceutical Sciences, Puri, Odisha, India, Pharmaceutics Department, for providing the facilities needed to conduct the research

Kaynakça

• Barzegar, JM., Javadzadeh, Y., Nokhodchi, A., Siahi- Shadbad, MR. (2005). Enhancement of dissolution rate of piroxicam using liquisolid compacts. Il Farmaco, 60(4), 361-365.